POST Online Media Lite Edition


Dynavax appoints Robert Janssen as chief medical officer

Staff writer |
Berkeley, Ca., USA - July 12, 2013, Berkeley, Ca., USA - Dynavax Technologies Corporation, a biopharmaceutical company, announced the appointment of Robert Janssen as chief medical officer and vice president, clinical development.

Article continues below

Dr. Janssen most recently served as Dynavax's Vice President, Medical Affairs since November 2012 and was previously Senior Director, Clinical Development at Dynavax from 2010 through 2012, during which time he was extensively involved with Phase 3 clinical development of HEPLISAV and its US and European licensing applications.

Prior to joining Dynavax, Dr. Janssen was Vice President, Medical Affairs at Gilead from 2008 to 2010 where he was responsible for oversight of physician and health care provider education focused on HIV and hepatitis B therapies. Until 2008, Dr. Janssen spent 23 years at the US Centers for Disease Control and Prevention (CDC), most recently as the Director of the Division of HIV/AIDS Prevention from 2000 to 2008.

Dr. Janssen received a Bachelor of Arts degree with Honors in Humanities from Stanford University and his M.D. degree from the University of Southern California. He is a neurologist with training in virology at the University of Pennsylvania.


What to read next

Dynavax promotes J. Tyler Martin to president
Dynavax appoints Francis R. Cano to the board
Gert-Jan Janssen appointed CFO at